title: Korean guideline for iron chelation therapy in transfusion-induced iron overload.
abstract: Many Korean patients with transfusion-induced iron overload experience serious clinical sequelae, including organ damage, and require lifelong chelation therapy. However, due to a lack of compliance and/or unavailability of an appropriate chelator, most patients have not been treated effectively. Deferasirox (DFX), a once-daily oral iron chelator for both adult and pediatric patients with transfusion-induced iron overload, is now available in Korea. The effectiveness of deferasirox in reducing or maintaining body iron has been demonstrated in many studies of patients with a variety of transfusion-induced anemias such as myelodysplastic syndromes, aplastic anemia, and other chronic anemias. The recommended initial daily dose of DFX is 20 mg/kg body weight, taken on an empty stomach at least 30 min before food and serum ferritin levels should be maintained below 1000 ng/mL. To optimize the management of transfusion-induced iron overload, the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) reviewed the general consensus on iron overload and the Korean data on the clinical benefits of iron chelation therapy, and developed a Korean guideline for the treatment of iron overload.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Jang
authors.forename: Je-Hwan
authors.initials: JH
authors.lastname: Lee
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Yoon
authors.forename: Deog-Yeon
authors.initials: DY
authors.lastname: Jo
authors.forename: Hyeoung-Joon
authors.initials: HJ
authors.lastname: Kim
authors.forename: Jooseop
authors.initials: J
authors.lastname: Chung
authors.forename: Jong Wook
authors.initials: JW
authors.lastname: Lee
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy; D001565:Benzoates / Q000627:therapeutic use; D015913:Chelation Therapy / Q000379:methods*; D000077588:Deferasirox; D000077543:Deferiprone; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000628:therapy; D011728:Pyridones / Q000627:therapeutic use; D056910:Republic of Korea; D065227:Transfusion Reaction; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D000077588:Deferasirox
keywords: Deferasirox; Iron Overload; Korean Guideline